Holy Stone Healthcare Co., Ltd. (TPEX:4194)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
7.10
-0.06 (-0.84%)
Mar 10, 2026, 2:03 PM CST
-30.73%
Market Cap 1.05B
Revenue (ttm) 47.51M
Net Income (ttm) -139.59M
Shares Out 145.97M
EPS (ttm) -0.96
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 71,880
Average Volume 87,414
Open 7.17
Previous Close 7.16
Day's Range 6.97 - 7.51
52-Week Range 5.32 - 12.65
Beta 0.73
RSI 42.65
Earnings Date Mar 26, 2026

About Holy Stone Healthcare

Holy Stone Healthcare Co., Ltd. develops and sells hyaluronic acid-related therapeutic products in Taiwan. The company offers RenehaVis, a product designed to relive pain and stiffness of the knee joint; SportVis, a treatment to relive the pain and optimize the recovery of tendon and ligament injuries; TRUD, a treatment that allows mucosal tissue to heal naturally and reduces the symptoms of ulcerative colitis; and GAF, a treatment for anal mucosal lesions. It is also developing IBD98-M, which is in Phase II a clinical trials for the treatment ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 4194
Full Company Profile

Financial Performance

In 2024, Holy Stone Healthcare's revenue was 118.77 million, a decrease of -49.86% compared to the previous year's 236.89 million. Losses were -183.49 million, -36.59% less than in 2023.

Financial Statements

News

There is no news available yet.